RE: RE: RE: ApoA1 Keep in mind that in this paper, they used mice genetically engineered to have extremely low or high apoAI/HDL levels. Not exactly in the physiological relevant range. However, I found this statement in the discussion very reassuring:
". Further, during the conduct of the present studies, a large meta analysis of randomized controlled trials of lipid-altering therapies was reported that suggested an inverse relationship between plasma HDL cholesterol levels and incidence of cancer development during the conduct of the trials (59). Specifically, for every 10 mg/dL increase in plasma HDL cholesterol level among trial participants, a significant 36% lower risk of cancer incidence was noted during over 625,000 person-years of followup and >8,000 incident cancers cumulatively amongst the trials included in the meta analysis (59). While such meta analyses are hypotheses generating, and cannot serve as proof for an anticancer effect of HDL/apoA1 in humans, they are provocative. It is thus also of interest that another recent population based prospective cohort study (n=17,779) in China similarly reported a 2-fold cancer risk associated with low HDL cholesterol (60). Collectively, the present studies, couple with these epidemiological studies in humans, suggest that HDL may be linked to tumor cell biology in humans. "